Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of oral daily
administration of TTI-101 over a 12-week treatment duration in participants with idiopathic
pulmonary fibrosis (IPF).